Torrent Acquires Chronic Brands From Dr Reddy’s, Folds Up US Liquids Business
Aczone Tracks Well Post Launch
Torrent is recalibrating strategy with the addition of chronic therapies from Dr Reddy’s while it folds up an unsustainable liquids business in US. The latter resulted in the company reporting a Q4 loss but a timely bonus share issue propped up investor sentiment.
You may also be interested in...
Glenmark readies scale up in the respiratory segment, with Ryaltris set for a US debut and a filing for a generic rival to Flovent anticipated. Running a facility in that market, though, is not an easy task, says the firm's leadership.
A few cases of COVID-19 relapse have Twitter abuzz about the need for data on Paxlovid’s effectiveness, particularly against the Omicron variant and in vaccinated individuals. Despite regulatory approval in India, the drug has not yet been included in treatment guidelines and a debate on recommended dosage now complicates matters
India’s Torrent has seen back-to-back decline in its US business, reporting a 20% drop in revenues in Q3 FY22 alone, as new launches are predicted to come to the rescue in the US market. The company remains stable domestically with new launches as it sees 15% growth in the Indian market.